Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.

Jonstam KarinBrian N SwansonLeda P MannentLars-Olaf CardellNian TianYing WangDonghui ZhangChunpeng FanGabriele HoltappelsJennifer D HamiltonAnnette GrabherNeil M H GrahamGianluca PirozziClaus Bachert

Published in: Allergy (2019)

Dupilumab treatment reduced multiple biomarkers of type 2 inflammation in nasal secretions and polyp tissues of patients with CRSwNP, demonstrating that antagonism of IL-4Rα signaling suppresses IL-4-/IL-13-dependent processes, such as mucosal IgE formation, as well as the expression of chemokines attracting inflammatory cells to the nasal mucosa.

Keyphrases

chronic rhinosinusitis
atopic dermatitis
oxidative stress
induced apoptosis
poor prognosis
signaling pathway
gene expression
cell cycle arrest
combination therapy
cell death
cell proliferation